NDC 51662-1555

HYALURONIDASE

Hyaluronidase

HYALURONIDASE is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Hf Acquisition Co Llc, Dba Healthfirst. The primary component is Hyaluronidase (human Recombinant).

Product ID51662-1555_c3f1db01-58c0-2226-e053-2a95a90a8b33
NDC51662-1555
Product TypeHuman Prescription Drug
Proprietary NameHYALURONIDASE
Generic NameHyaluronidase
Dosage FormInjection, Solution
Route of AdministrationSUBCUTANEOUS
Marketing Start Date2021-06-04
Marketing CategoryBLA /
Application NumberBLA021859
Labeler NameHF Acquisition Co LLC, DBA HealthFirst
Substance NameHYALURONIDASE (HUMAN RECOMBINANT)
Active Ingredient Strength150 [USP'U]/mL
Pharm ClassesEndoglycosidase [EPC],Glycoside Hydrolases [CS]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 51662-1555-1

1 VIAL in 1 BOX (51662-1555-1) > 1 mL in 1 VIAL
Marketing Start Date2021-06-04
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "HYALURONIDASE" or generic name "Hyaluronidase"

NDCBrand NameGeneric Name
51662-1555HYALURONIDASEHYALURONIDASE
0548-9090AMPHADASEhyaluronidase
17478-560HydaseHyaluronidase

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.